Cathay Biotech (688065) 华安证券·2025-03-13 07:10Investment Rating - Investment Rating: Buy (Maintain) [2] Core Views - The company is expected to achieve a significant revenue increase in 2024, with projected revenue of 2.956 billion yuan, a year-on-year increase of 39.84%, and a net profit of 487 million yuan, up 32.80% year-on-year [6] - The collaboration with Ningde Times marks a key milestone in commercializing bio-based polyamide materials, enhancing market penetration in the new energy sector [7] - The long-term growth path is clear, supported by technological advantages and policy incentives, particularly in the context of carbon neutrality goals [8] Summary by Sections Financial Performance - In 2024, the company anticipates a total revenue of 2.956 billion yuan, with a profit total of 546 million yuan and a net profit attributable to shareholders of 487 million yuan [5] - The fourth quarter of 2024 is projected to generate revenue of 741 million yuan, a year-on-year increase of 35.12%, and a net profit of 142 million yuan, up 168.91% year-on-year [6] Business Development - The demand for long-chain dicarboxylic acids is recovering, with new product capacity for sebacic acid driving significant growth in production and sales [6] - The establishment of a joint venture with Ningde Times focuses on the development and production of bio-based composite materials, marking a substantial step in the commercialization of these materials [7] Market Outlook - The company is positioned to benefit from structural advantages in synthetic biology technology, with a strong market share in bio-based long-chain dicarboxylic acids [8] - The global implementation of the EU carbon border tax (CBAM) in 2026 is expected to enhance the competitive edge of the company's bio-based materials in export-oriented industries [9] Investment Recommendations - The forecast for net profit attributable to shareholders for 2024-2026 is 473 million, 655 million, and 857 million yuan, respectively, with corresponding growth rates of 29.1%, 38.4%, and 30.8% [10]